Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes
- PMID: 19289741
- DOI: 10.1212/01.wnl.0000344417.42972.54
Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes
Abstract
In this essay, we draw attention to some recent downsides and surprises of multiple sclerosis (MS) therapeutics. These include experiences with recent head-to-head trials of interferon-beta and glatiramer acetate, dose escalation trials, frustrating efforts with progressive MS trials, failures of smart concepts and designer therapies, and harsh lessons from newly observed adverse reactions.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical